1. Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease
- Author
-
Chertow, Glenn M, Appel, Gerald B, Block, Geoffrey A, Chin, Melanie P, Coyne, Daniel W, Goldsberry, Angie, Kalantar-Zadeh, Kamyar, Meyer, Colin J, Molitch, Mark E, Pergola, Pablo E, Raskin, Philip, Silva, Arnold L, Spinowitz, Bruce, Sprague, Stuart M, and Rossing, Peter
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,Obesity ,Clinical Research ,Prevention ,Kidney Disease ,Diabetes ,Nutrition ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Renal and urogenital ,Metabolic and endocrine ,Cancer ,Aged ,Blood Glucose ,Body Weight ,Diabetes Mellitus ,Type 2 ,Diabetic Nephropathies ,Disease Progression ,Double-Blind Method ,Female ,Glomerular Filtration Rate ,Glycated Hemoglobin ,Humans ,Male ,Middle Aged ,Oleanolic Acid ,Renal Insufficiency ,Chronic ,Waist Circumference ,Bardoxolone methyl ,Chronic kidney disease ,Metabolic effects ,HbA(1c) ,Randomized clinical trial ,Endocrinology & Metabolism ,Clinical sciences - Abstract
AimsObesity is associated with progression of chronic kidney disease (CKD). Treatment with bardoxolone methyl in a multinational phase 3 trial, Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), resulted in increases in estimated glomerular filtration rate (eGFR) with concurrent reductions in body weight. We performed post-hoc analyses to further characterize reductions in body weight with bardoxolone methyl.MethodsEligible patients with type 2 diabetes (T2DM) and CKD stage 4 (eGFR 15 to
- Published
- 2018